Biocon secures $54m insulin tender in Malaysia
after close1 source ↓written by the desknot a recommendation
- valued
- $54 million
Biocon, in collaboration with Duopharma Biotech, has won three insulin contracts from Malaysia’s Ministry of Health, valued at $54 million. This deal enhances Biocon's presence in the Malaysian market, reflecting its commitment to expanding its generics portfolio.
The contracts may boost near-term revenue and strengthen market confidence in Biocon's growth strategy in the Pharma sector.
This development underscores the increasing demand for insulin in Malaysia, positioning Biocon favorably against competitors.
Not investment advice. For informational purposes only.